The original drug of domestic company Biocad(participant of "Made in Russia") for treatment of rheumatoid arthritis and cytokine release syndrome in a severe course of coronavirus received registration in Belarus, the company said.

This country was the first foreign country that registered the medicine. Now an application for its registration has been filed in Kazakhstan.

"The Ministry of Health of the Republic of Belarus has approved the use of the drug levilimab (trade name Ilsira)," the report said.

As it was specified in Biocad, levilimab is an original Russian genetically engineered biological drug that has been used in therapy for cytokine release syndrome in the severe course of covid for more than a year.

Levilimab was originally developed to treat arthritis. It was later found to be able to arrest the cytokine storm in coronavirus. After relevant clinical trials in June last year, the drug's spectrum of use was expanded. Today, levilimab is on the list of vital drugs in Russia.

The company has invested 300 million rubles in the clinical development.

"Registration of levilimab in the Republic of Belarus will open access to proactive therapy for life-threatening conditions in patients with COVID-19, as well as provide access for patients with a confirmed diagnosis of rheumatoid arthritis to genetically engineered biological therapy designed, if prescribed in time, to halt the progression of rheumatoid arthritis and avoid disabilities," the company concluded.

Made in Russia // Made in Russia

Author: Ksenia Gustova